Datar Cancer Genetics
PrivateLast Round
VC Round
Nov 27, 2024
Company Overview
Datar Cancer Genetics is a global molecular oncology company that develops non-invasive diagnostic solutions for cancer. The company specializes in liquid biopsies, which use blood samples to detect cancer early, guide treatment options, and monitor disease progression or recurrence. Its portfolio includes a range of tests such as Trucheck™, Cancertrack™, and Exacta™, which have received CE marks. Datar Cancer Genetics has also been granted multiple 'Breakthrough Device Designations' by the U.S. Food and Drug Administration (FDA) for its early detection tests for breast, prostate, and brain cancers. The company operates accredited and certified laboratories in India and the United Kingdom, serving patients and clinicians globally. It is a privately held, venture-backed company.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Devices, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Datar Cancer Genetics Comps
Public and private peers based on sector, stage, and business model.
Datar Cancer Genetics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Nov 27, 2024 |
Datar Cancer Genetics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alkemi Growth Capital | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 23, 2025
Launched NaturaGene-AI, an advanced oncology testing panel.
- Feb 11, 2025
Dr. Massimo Cristofanilli appointed as Strategic Advisor.
Datar Cancer Genetics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Datar Cancer Genetics's valuation, stock price, and market status.
